Medivation Branches Out With Phase III PARP Inhibitor From BioMarin
This article was originally published in The Pink Sheet Daily
Deal is structured with significant upfront cash at $410m, but relatively low earn-out potential for a Phase III cancer candidate. It also gives Medivation two late-stage oncology compounds beyond Xtandi; CEO David Hung outlines strategy.
You may also be interested in...
LSI 2023: Intuitive Alums On Dawning Of Robotic Surgery To Digital OR Future
Robotic surgery pioneer and co-founder of Intuitive Surgical Frederic Moll joined Daniel Hawkins, Intuitive’s first non-technical hire, for a discussion on the evolution of surgical robotics and outlook for the future.
EU Sets New Date For Publication Of Delayed Pharma Revision Proposals
Lengthy legislative procedures are expected after the commission publishes its “pharma package” and the “patent package,” which are now due towards the end of April.
High Ambitions For EU DARWIN Platform After Delivery Of First RWE Studies
Within one year of its establishment, DARWIN EU has started reaping benefits for EU drug regulators commissioning studies using real-world data to better understand diseases, populations and the uses and effects of medicines. The studies can be performed faster, cheaper and at increased capacity.